Edition:
United States

Vertex Pharmaceuticals Inc (VRTX.O)

VRTX.O on Nasdaq

176.02USD
10:56am EDT
Change (% chg)

$-2.07 (-1.16%)
Prev Close
$178.09
Open
$179.15
Day's High
$179.15
Day's Low
$175.63
Volume
183,404
Avg. Vol
1,202,950
52-wk High
$195.81
52-wk Low
$151.80

About

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $45,612.65
Shares Outstanding(Mil.): 256.12
Dividend: --
Yield (%): --

Financials

  VRTX.O Industry Sector
P/E (TTM): 77.88 95.83 34.03
EPS (TTM): 2.29 -- --
ROI: 13.32 7.72 12.70
ROE: 16.70 8.23 17.29

Vertex Pharmaceuticals expands into Duchenne gene therapy with new deals

Vertex Pharmaceuticals Inc said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20190606:nBw4wRKsa on Thursday it would acquire privately held Exonics Therapeutics for an upfront payment of $245 million and potential milestone payments of up to $750 million.

Jun 06 2019

Vertex Pharmaceuticals expands into Duchenne gene therapy with new deals

June 6 Vertex Pharmaceuticals Inc said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20190606:nBw4wRKsa on Thursday it would acquire privately held Exonics Therapeutics for an upfront payment of $245 million and potential milestone payments of up to $750 million.

Jun 06 2019

Vertex to file for approval of cystic fibrosis therapy in 2019

May 30 Vertex Pharmaceuticals Inc said on Thursday it will apply for regulatory approval later this year for its triple combination of drugs to treat life-shortening genetic condition cystic fibrosis.

May 30 2019

BRIEF-Cincor Pharma Closes $50 Mln Series A Financing

* CINCOR PHARMA IN-LICENSES ALDOSTERONE SYNTHASE INHIBITOR, CIN-107, AND CLOSES $50 MILLION SERIES A FINANCING

May 14 2019

BRIEF-Crispr Therapeutics And Vertex Announce FDA Fast Track Designation For CTX001 For Treatment Of Beta Thalassemia

* CRISPR THERAPEUTICS AND VERTEX ANNOUNCE FDA FAST TRACK DESIGNATION FOR CTX001 FOR THE TREATMENT OF BETA THALASSEMIA Source text for Eikon: Further company coverage:

Apr 16 2019

Vertex cystic fibrosis triple combo therapy succeeds in important trials

Vertex Pharmaceuticals Inc on Wednesday said its triple-combination treatment for cystic fibrosis led to significant lung function improvement in two late-stage studies, paving the way for a therapy that could eventually address 90 percent of people with the life-shortening genetic condition.

Mar 06 2019

UPDATE 2-Vertex cystic fibrosis triple combo therapy succeeds in important trials

March 6 Vertex Pharmaceuticals Inc on Wednesday said its triple-combination treatment for cystic fibrosis led to significant lung function improvement in two late-stage studies, paving the way for a therapy that could eventually address 90 percent of people with the life-shortening genetic condition.

Mar 06 2019

Vertex Pharma boots out COO for 'personal behavior' violations

Vertex Pharmaceuticals Inc said on Wednesday it had terminated the employment of its chief operating officer and interim chief financial officer, Ian Smith, citing "personal behavior" that violated its code of conduct.

Jan 23 2019

UPDATE 1-Vertex Pharma boots out COO for "personal behavior" violations

Jan 23 Vertex Pharmaceuticals Inc said on Wednesday it had terminated the employment of its chief operating officer and interim chief financial officer, Ian Smith, citing "personal behavior" that violated its code of conduct.

Jan 23 2019

Vertex Pharma terminates interim CFO's employment for code violations

Jan 23 Vertex Pharmaceuticals Inc said on Wednesday it had terminated the employment of its chief operating officer and interim chief financial officer, Ian Smith, citing personal behavior that violated its code of conduct.

Jan 23 2019

Earnings vs. Estimates